Page 52 - AN-4-4

Advanced Neurology Lipid metabolism and Parkinson’s disease

doi: 10.1523/JNEUROSCI.6348-09.2010 lysophosphatidylcholine in human Jurkat T cells. Acta
Pharmacol Sin. 2006;27(6):700-707.
116. Schneider JS, Roeltgen DP, Mancall EL, Chapas-Crilly J,
Rothblat DS, Tatarian GT. Parkinson’s disease: Improved doi: 10.1111/j.1745-7254.2006.00339.x
function with GM1 ganglioside treatment in a randomized
placebo-controlled study. Neurology. 1998;50(6):1630-1636. 127. García-Morales V, Montero F, González-Forero D,
et al. Membrane-derived phospholipids control
doi: 10.1212/wnl.50.6.1630 synaptic neurotransmission and plasticity. PLoS Biol.
117. Schneider JS, Aras R, Williams CK, Koprich JB, Brotchie JM, 2015;13(5):e1002153.
Singh V. GM1 Ganglioside modifies α-synuclein toxicity and doi: 10.1371/journal.pbio.1002153
is neuroprotective in a rat α-synuclein model of Parkinson’s
disease. Sci Rep. 2019;9(1):8362. 128. Hao Y, Guo M, Feng Y, Dong Q, Cui M. Lysophospholipids
and their G-coupled protein signaling in Alzheimer’s
doi: 10.1038/s41598-019-42847-x disease: From physiological performance to pathological
118. Galleguillos D, Wang Q, Steinberg N, et al. Anti- impairment. Front Mol Neurosci. 2020;13:58.
inflammatory role of GM1 and other gangliosides on doi: 10.3389/fnmol.2020.00058
microglia. J Neuroinflammation. 2022;19(1):9.
129. Geraldo LHM, Spohr TCLDS, Amaral RFD, et al. Role of
doi: 10.1186/s12974-021-02374-x lysophosphatidic acid and its receptors in health and disease:
119. Sonnino S. The relationship between depletion of brain Novel therapeutic strategies. Signal Transduct Target Ther.
GM1 ganglioside and Parkinson’s disease. FEBS Open Bio. 2021;6(1):45.
2023;13(9):1548-1557. doi: 10.1038/s41392-020-00367-5
doi: 10.1002/2211-5463.13554 130. Yilmaz A, Ashrafi N, Ashrafi R, et al. Lipid profiling
120. Chiricozzi E, Mauri L, Lunghi G, et al. Parkinson’s disease of Parkinson’s disease brain highlights disruption in
recovery by GM1 oligosaccharide treatment in the lysophosphatidylcholines, and triacylglycerol metabolism.
B4galnt1+/− mouse model. Sci Rep. 2019;9(1):19330. NPJ Parkinsons Dis. 2025;11(1):159.
doi: 10.1038/s41598-019-55885-2 doi: 10.1038/s41531-025-01023-x
121. Kumar R, Chowdhury S, Ledeen R. Alpha-synuclein and 131. Mu C, Shao K, Su M, et al. Lysophosphatidylcholine
GM1 ganglioside co-localize in neuronal cytosol leading promoting α-Synuclein aggregation in Parkinson’s disease:
to inverse interaction-relevance to Parkinson’s disease. Int J Disrupting GCase glycosylation and lysosomal α-Synuclein
Mol Sci. 2024;25(6):3323. degradation. NPJ Parkinsons Dis. 2025;11(1):47.
doi: 10.3390/ijms25063323 doi: 10.1038/s41531-025-00902-7
122. Chowdhury S, Wu G, Lu ZH, Kumar R, Ledeen R. Age-related 132. Hung ND, Sok DE, Kim MR. Prevention of 1-palmitoyl
decline in gangliosides GM1 and GD1a in non-CNS tissues lysophosphatidylcholine-induced inflammation by
of normal mice: Implications for peripheral symptoms of polyunsaturated acyl lysophosphatidylcholine. Inflamm Res.
Parkinson’s disease. Biomedicines. 2023;11(1):209. 2012;61(5):473-483.
doi: 10.3390/biomedicines11010209 doi: 10.1007/s00011-012-0434-x
123. Itokazu Y, Fuchigami T, Morgan JC, Yu RK. Intranasal 133. Zhao C, Tu J, Wang C, et al. Lysophosphatidylcholine binds
infusion of GD3 and GM1 gangliosides downregulates α-synuclein and prevents its pathological aggregation. Natl
alpha-synuclein and controls tyrosine hydroxylase gene in a Sci Rev. 2024;11(6):nwae182.
PD model mouse. Mol Ther. 2021;29(10):3059-3071. doi: 10.1093/nsr/nwae182
doi: 10.1016/j.ymthe.2021.06.005 134. Malik I, Turk J, Mancuso DJ, et al. Disrupted membrane
124. Chowdhury S, Kumar R, Zepeda E, DeFrees S, Ledeen R. homeostasis and accumulation of ubiquitinated proteins in
Synthetic GM1 improves motor and memory dysfunctions a mouse model of infantile neuroaxonal dystrophy caused
in mice with monoallelic or biallelic disruption of GM3 by PLA2G6 mutations. Am J Pathol. 2008;172(2):406-416.
synthase. FEBS Open Bio. 2023;13(9):1651-1657. doi: 10.2353/ajpath.2008.070823
doi: 10.1002/2211-5463.13669 135. Shin KC, Ali Moussa HY, Park Y. Cholesterol imbalance and
125. Wei J, Liu X, Xiao W, et al. Phospholipid remodeling and its neurotransmission defects in neurodegeneration. Exp Mol
derivatives are associated with COVID-19 severity. J Allergy Med. 2024;56(8):1685-1690.
Clin Immunol. 2023;151(5):1259-1268.
doi: 10.1038/s12276-024-01273-4
doi: 10.1016/j.jaci.2022.11.032
136. Zhang J, Liu Q. Cholesterol metabolism and homeostasis in
126. Im YJ, Lee YK, Chung HY, Im DS. Multiple actions of the brain. Protein Cell. 2015;6(4):254-264.

Volume 4 Issue 4 (2025) 46 doi: 10.36922/AN025320086